share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股變動聲明
SEC announcement ·  03/22 17:48
Moomoo AI 已提取核心訊息
CRISPR Therapeutics AG's Chief Executive Officer, Samarth Kulkarni, has engaged in a transaction involving the company's stock on March 20, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action reflects the CEO's dealings with the company's non-derivative securities. Investors are advised to note the involvement of a high-level executive in the company's stock transactions, which may be indicative of the company's internal confidence and future prospects.
CRISPR Therapeutics AG's Chief Executive Officer, Samarth Kulkarni, has engaged in a transaction involving the company's stock on March 20, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action reflects the CEO's dealings with the company's non-derivative securities. Investors are advised to note the involvement of a high-level executive in the company's stock transactions, which may be indicative of the company's internal confidence and future prospects.
CRISPR Therapeutics AG首席執行官薩瑪斯·庫爾卡尼已於2024年3月20日參與了一項涉及該公司股票的交易。該交易的細節，包括所涉及的股票數量和交易價格，尚未在公告中披露。該行動反映了首席執行官與公司非衍生證券的交易。建議投資者注意高級管理人員參與公司的股票交易，這可能表明公司的內部信心和未來前景。
CRISPR Therapeutics AG首席執行官薩瑪斯·庫爾卡尼已於2024年3月20日參與了一項涉及該公司股票的交易。該交易的細節，包括所涉及的股票數量和交易價格，尚未在公告中披露。該行動反映了首席執行官與公司非衍生證券的交易。建議投資者注意高級管理人員參與公司的股票交易，這可能表明公司的內部信心和未來前景。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息